Author: Matthew Nelson|| Date Published: July 30, 2019
Battelle has entered into a contractor agreement with the Defense Advanced Research Projects Agency to develop a platform designed to identify epigenome signatures that could be used to determine an individual™s exposure to materials associated with weapons of mass destruction.
Under DARPA™s Epigenetic Characterization and Observation program, Battelle said Monday it will identify unique signatures by comparing blood samples from individuals that have dealt with chemical, biological, pesticide or herbicide contaminants to those of control subjects.
œWe™ll be developing methods to identify these signatures and how to interpret them for attribution”what did the person handle, when and for how long, said Rachel Spurbeck, a principal research scientist and biologist at Battelle. œThis will even allow for diagnosing illnesses in individuals as a result of their exposure.
The nonprofit company said the proposed technology will trace a specific epigenome from a biological sample despite the absence of other physical evidence.
Virtualitics announced on LinkedIn Saturday that Nicole Diresta has been appointed vice president for public policy and planning. Diresta will oversee initiatives…
J2 Ventures has closed its $250 million Brookhaven Fund, an oversubscribed early-stage investment vehicle focused on dual-use technologies critical to…
The Department of Homeland Security’s Immigration and Customs Enforcement has started soliciting proposals for a potential two-year, $180 million contract…
The Department of Defense is conducting market research to assess industry capability and interest in supporting a planned indefinite-delivery/indefinite-quantity contract…
